Increased BLyS/BAFF levels have also been reported in the context of B-cell depletion using anti-CD20 (Rituximab) treatment of human patients presenting B-cell lymphoma [43]. Here, TNFSF13B is linked to B-cell non-Hodgkin lymphoma.